FLAGSTAFF, Ariz., Oct. 16, 2018 /PRNewswire-PRWeb/ -- Symple
Surgical Inc. (SSI) announced today that we have received a
National Institutes of Health (NIH) Small Business Innovation
Research (SBIR) Phase I Grant Award totaling $225,000.00. This award will leverage the ongoing
R&D and commercialization initiatives with Duke University to pursue the integration of
radiometric thermal feedback with the Symple Surgical microwave
ablation technology. As part of this award, both parties will
explore technological synergies and continue to strive toward
pre-clinical evidence from SSI's DirectAblate™ and GRIZZLY™ device
platforms.
Daniel J. Kasprzyk, President
& CEO commented: "We are very confident in the novel microwave
ablation technology that has been developed at SSI with our
talented and dedicated engineering team and technology partners at
Duke University. We place enormous
value on this strategic development partnership, which should
rapidly advance our platform to achieve human clinical evidence.
SSI has remained steadfast in our pursuit of next generation
ablation technology to provide controlled circumferential ablation,
thermal depth control, intimal/media vessel protection, and
procedural ablation feedback built into a single device."
Renal denervation is a minimally invasive vascular procedure
used to treat uncontrolled hypertension that radiometric thermal
feedback together with microwave ablation technology may offer
several potential patient benefits over drug therapy. The market is
predicted to grow significantly due to the surge in global
hypertension rates. There are several approved, carefully designed
clinical trials in the US, EU and Asia focused on moving the field of
sympathetic nerve modulation forward.
Dr. Paolo Maccarini, Ph.D.,
observes: "Resistant Hypertension is a disease that has a global
impact. Symple Surgical's novel microwave ablation catheter is
poised to be a unique therapy that can provide safe and effective
treatment of this disease via a procedure called Renal Sympathetic
Denervation. Together with my experience and research in the field
of microwave radiometric techniques, I believe we can increase the
efficacy of the procedure by providing real-time temperature
feedback of the ablation zone. Symple Surgical has just been
awarded a Phase 1 NIH SBIR grant to pursue this with my team at
Duke University."
All future research reported was supported by the National
Heart, Lung and Blood Institute of the NIH under Award Number
1-R43-HL144416-01
For more information:
Whitney Cunningham (928)
774-1478
Aspey, Watkins & Diesel, PLLC
About Symple Surgical Inc.
Symple Surgical Inc. (SSI) is a privately held early stage medical
device company with engineering and product development offices in
Flagstaff, AZ. SSI has raised
approximately $3.0M in angel round
financing since 2012. SSI is focused on developing a medical device
ablation platform to help millions of patients for multiple
possible applications, including treatment of Barrett's esophagus,
esophageal adenocarcinoma, pulmonary hypertension, resistant
hypertension and other ablation opportunities.
Symple Surgical Inc products are currently not available for
clinical evaluation or sale.
SOURCE Symple Surgical Inc.